GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tevogen Bio Holdings Inc (NAS:TVGN) » Definitions » Treasury Stock

TVGN (Tevogen Bio Holdings) Treasury Stock : $0.00 Mil (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Tevogen Bio Holdings Treasury Stock?

Treasury stock is the portion of shares that a company keeps in their own treasury. Tevogen Bio Holdings's treasury stock for the quarter that ended in Dec. 2024 was $0.00 Mil.

Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place.


Tevogen Bio Holdings Treasury Stock Historical Data

The historical data trend for Tevogen Bio Holdings's Treasury Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tevogen Bio Holdings Treasury Stock Chart

Tevogen Bio Holdings Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Treasury Stock
- - - -

Tevogen Bio Holdings Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Treasury Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Tevogen Bio Holdings Treasury Stock Calculation

The portion of shares that a company keeps in their own treasury. Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place. These shares don't pay dividends, have no voting rights, and should not be included in shares outstanding calculations.


Tevogen Bio Holdings Business Description

Traded in Other Exchanges
Address
15 Independence Boulevard, Warren, NJ, USA, 07059
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.